Skip to main content
OpenTrials
Completed

NCT Number: NCT04490057

A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV

Many people living with HIV (PLWH) smoke. Smoking in these individuals is often undertreated. This study plans to assess the ability of various clinical pathways involving tobacco treatment medications and contingency management (paying smokers for not smoking) to improve smoking cessation in a group of PLWH.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Bridgeport Hospital Infectious Disease Clinic, Bridgeport, Connecticut, United States

Loading trial locations.

About this study

Using a Sequential Multiple Assignment Randomized Trial (SMART) design, this project is a two-arm, two-stage randomized trial of 320 adult PWH who smoke cigarettes and receive care in one of three health systems (targeted enrollment changed from 632 to 320 with NCI approval and IRB protocol amendment). At inception, participants will be randomized to either combination nicotine replacement therapy (NRT, patch + short-acting NRT) or combination NRT+contingency management (CM). At 12 weeks, responders (non-smoking participants confirmed by exhaled carbon monoxide [eCO] or collateral verification) in both arms will receive 12 more weeks of the same treatment. Non-responders (participants with continued smoking by self-report and/or eCO) in both the NRT and NRT+CM arms will be re-randomized to 12 weeks of treatment, either with medication switch to oral medication, varenicline or bupropion, or intensified level of CM (start CM if no CM during first 12 weeks, or CM with higher reward schedule ["CM plus"] if NRT+CM group initially). The intervention will be delivered by trained clinical pharmacists. The primary outcomes will be self-reported reduction in average cigarettes smoked per day at 24 weeks and 12 weeks (primary outcome changed from eCO-confirmed abstinence to self-reported abstinence with NCI approval and IRB protocol amendment). The specific aims of the proposed study are to: (1) identify the optimal adaptive approach to promote reduced tobacco use (changed from eCO-confirmed smoking abstinence with NCI approval and protocol amendment) (2) study the effectiveness of various adaptive strategies on CD4 count, HIV viral suppression, and VACS index (validated measure of morbidity and mortality risk); and (3) grounded in implementation science and using aHybrid Effectiveness-Implementation Type I design, identify barriers and facilitators to delivering our intervention to inform future implementation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • HIV positive;
  • >= 18 years old
  • Receiving HIV care at Yale-New Haven Hospital, Bridgeport Hospital, Mount Sinai Hospital, or SUNY Downstate STAR clinic;
  • Have smoked >= 100 cigarettes in lifetime;
  • Currently smokes some days or every day;
  • Smokes, on average, >= 5 cigarettes per day;
  • Able to provide written informed consent.

Exclusion criteria

  • Using only non-cigarette nicotine products (i.e., e-cigs, Juul, etc.);
  • Currently using NRT, VAR, or bupropion (defined as use in the prior 7 days);
  • Self-report or urine testing confirming pregnancy, nursing, or trying to conceive;
  • Life-threatening or unstable medical, surgical, or psychiatric condition;
  • Inability to provide at least one collateral contact (family member or friend);
  • Living out of state;
  • Unable to read or understand English (except at Mount Sinai site).

Treatment and study plan

Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler

Drug

Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.

Varenicline or bupropion

Drug

Participants will be prescribed varenicline (Chantix) or bupropion (Wellbutrin).

Contingency Management

Behavioral

Participants will be financially rewarded for abstinence to tobacco.

Primary outcomes

  1. Self Reported Reduction in Average Cigarettes Smoked Per Day at 12 Weeks

    Time frame: Week 12

    Self reported reduction in average cigarettes smoked per day at 12 weeks

  2. Self Reported Reduction in Average Cigarettes Smoked Per Day at 24 Weeks

    Time frame: 24 weeks

    Self reported reduction in cigarettes smoked per day at 24 weeks

Secondary outcomes

  1. Exhaled Carbon Monoxide (eCO) Confirmed Smoking Abstinence at 12 Weeks

    Time frame: 12 weeks from baseline

    Number of participants with smoking abstinence confirmed by exhaled carbon monoxide or next closest informant verification

  2. Exhaled Carbon Monoxide (eCO) Confirmed Smoking Abstinence at 24 Weeks

    Time frame: 24 weeks from baseline

    Number of participants with smoking abstinence confirmed by exhaled carbon monoxide or next closest informant verification

  3. VACS Index 2.0 Score

    Time frame: 24 weeks from baseline

    The Veterans Aging Cohort Study (VACS) 2.0 Index is A validated measure of morbidity and mortality. It estimates risk of 5-year all-cause mortality in patients with HIV. Total score range of 0-129. A higher total score indicates a greater risk of adverse health outcomes.

  4. CD4 Count

    Time frame: 24 weeks from baseline

    CD4 lymphocyte cell count. Normal range is 500-1200 cells per cubic millimeter. As HIV infection progresses, CD4 count drops.

  5. HIV Viral Load, Detectable

    Time frame: 24 weeks from baseline

    HIV viral load greater than 200 copies per milliliter of blood and detectable on standard lab test

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Acronym: SMARTTT

Important dates

Study start
2020
Primary completion
2024
Study completion
2025
First posted
Jul 28, 2020
Registry last updated
Jan 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.